Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss
Beginning Balance (in shares) at Dec. 31, 2021			34,333
Beginning Balance at Dec. 31, 2021	$ 1,583,321	$ (12,053)	$ 343	$ 13,662	$ (34,131)	$ 1,698,156	$ 22,078	$ (128,840)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	59,321					59,321
Other comprehensive income (loss)
Cumulative translation adjustment	(6,191)							(6,191)
Issuance of common stock in connection with:
Exercise of options (in shares)			26
Exercise of options	923			923
Restricted share grants (in shares)			134
Restricted share grants	(7,834)		$ 2	(7,836)
Stock units issued under incentive compensation plan	1,664			1,664
Purchase and retirement of common stock (in shares)			(22)
Purchase and retirement of common stock	(3,098)			(3,098)
Conversion of convertible senior notes due 2023	(2)			(2)
Share-based compensation	5,967			5,967
Reclassification of negative additional paid-in capital	0			22,851		(22,851)
Ending Balance (in shares) at Mar. 31, 2022			34,471
Ending Balance at Mar. 31, 2022	$ 1,622,018		$ 345	0		1,756,704		(135,031)
Beginning Balance (in shares) at Dec. 31, 2022	34,026		34,026
Beginning Balance at Dec. 31, 2022	$ 1,681,721		$ 340	0		1,858,103		(176,722)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	47,547					47,547
Other comprehensive income (loss)
Cumulative translation adjustment	9,850							9,850
Issuance of common stock in connection with:
Exercise of options (in shares)			14
Exercise of options	449			449
Restricted share grants (in shares)			55
Restricted share grants	(9,513)		$ 1	(9,514)
Stock units issued under incentive compensation plan	2,274			2,274
Purchase and retirement of common stock (in shares)			(112)
Purchase and retirement of common stock	(17,799)		$ (1)	(17,798)
Conversion of convertible senior notes due 2023	(6)			(6)
Share-based compensation	6,365			6,365
Reclassification of negative additional paid-in capital	$ 0			18,230		(18,230)
Ending Balance (in shares) at Mar. 31, 2023	33,983		33,983
Ending Balance at Mar. 31, 2023	$ 1,720,888		$ 340	$ 0		$ 1,887,420		$ (166,872)